Theorem Clinical Research

United States

AWARE for All Clinical Research Education Day returns to Boston

Monday, August 4, 2014 02:53 PM

The Center for Information and Study on Clinical Research Participation (CISCRP), a nonprofit organization dedicated to engaging the public and patients as partners in the clinical research process, has announced the return of AWARE for All Boston, a free event designed to promote understanding and dialogue around clinical research participation.

More... »


Optim Oncology, Urology Centers of Oklahoma join U.S. Oncology Network

Monday, August 4, 2014 01:59 PM

Optim Oncology and Urology Centers of Oklahoma, divisions of Oklahoma Multispecialty Group, have joined U.S. Oncology Network, a network of integrated, community-based, physician-owned oncology practices dedicated to advancing high-quality, evidence-based cancer care.

More... »


FDA approves Jardiance to treat type 2 diabetes

Friday, August 1, 2014 01:33 PM

The FDA has approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes.

More... »

Rho named a Best Place to Work by Triangle Business Journal

Thursday, July 31, 2014 11:36 AM

Rho, a CRO focused on bringing new products to market through a full range of product development services, has been named by Triangle Business Journal a winner of Best Places to Work. The award is part of the publication's annual Best Places to Work Awards program and recognizes Rho’s achievements in creating a positive work environment that attracts and retains employees through a combination of benefits, working conditions and company culture.

More... »

NIH programs to focus on emerging areas of science

Wednesday, July 30, 2014 12:40 PM

Scientific areas ripe for targeted investments in technology development and research to improve health are the focus of new programs of the NIH’s Common Fund. The programs include work to facilitate the study of how sugar modifications affect proteins, to understand the arrangement of DNA within cells in four dimensions and to enable the development of new therapies that allow control of organ function through manipulation of nerves.

More... »

Life expectancy gains threatened as more older Americans suffer from multiple medical conditions

Friday, July 25, 2014 01:01 PM

With nearly four in five older Americans living with multiple chronic medical conditions, a new study by researchers at Johns Hopkins Bloomberg School of Public Health finds the more ailments you have after retirement age, the shorter your life expectancy. The analysis, one of the first to examine the burden of multiple chronic conditions on life expectancy among the elderly, may help explain why increases in life expectancy among older Americans are slowing.

More... »

$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research

Friday, July 25, 2014 12:50 PM

The Broad Institute has announced an unprecedented commitment of $650 million from philanthropist Ted Stanley aimed at galvanizing scientific research on psychiatric disorders and bringing new treatments based on molecular understanding to hundreds of millions of people around the world.

More... »

Changes in generic pill color and shape disrupt use

Wednesday, July 23, 2014 10:38 AM

Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women’s Hospital (BWH) have found variation in appearance of generic drugs is associated with a greater risk of patients stopping their essential post-heart attack drugs.

More... »

Butrans Transdermal System CIII receives new dosage strength approval

Wednesday, July 23, 2014 08:00 AM

Purdue Pharma has announced that the FDA approved a new 7.5mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans now will be available: 5mcg/hour, 7.5mcg/hour, 10mcg/hour, 15mcg/hour and 20mcg/hour. The Butrans Transdermal System also is approved to allow the use of two patches to facilitate dose adjustments during titration. The total dose from both patches should not exceed 20mcg/hour. Purdue expects to launch Butrans 7.5mcg/hour commercially in the U.S. in October 2014.

More... »

Ruthigen treats first human subjects in clinical trial for RUT58-60

Tuesday, July 22, 2014 08:00 AM

Ruthigen, a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, has treated the first human subjects with its drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs